Is WAY a Buy? What to Consider in 2026
Short answer
The bull case for Waystar Holding (WAY) rests on AI-driven revenue cycle automation: Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026. Revenue (TTM) is ~$1.16B. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Whether WAY is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics. Its platform sits between roughly a million providers and the payers that reimburse them, processing billions of transactions a year, and the company leans heavily on automation and AI to reduce the manual work in medical billing. Provider-side solutions make up the large majority of revenue and carry high margins, with patient-payment tools rounding out the mix. The investment picture is one of a scaled, sticky software business that turned the corner on GAAP profitability after its 2024 IPO. Revenue grew about 22% year over year in Q1 2026 (roughly 11% organic, the rest from the Iodine Software acquisition), net revenue retention sits near 111%, and adjusted EBITDA margins run in the low-40s percent. The debate is less about whether the business works and more about valuation: at a mid-30s P/E and a market cap several times trailing revenue, the stock already embeds expectations for sustained growth, successful acquisition integration, and further margin gains.
What's the case for buying WAY?
1. AI-driven revenue cycle automation
Waystar has pushed AI features across claims, denials, and prior authorization, and management said AI-powered capabilities drove roughly 40% of new bookings in Q1 2026. Because medical billing is labor-intensive and error-prone, automation that lifts clean-claim rates and recovers denials is a concrete efficiency pitch to providers. This is the clearest lever the company points to for both new-logo wins and expansion within existing accounts.
2. Land-and-expand with high retention
Net revenue retention of about 111% means existing customers spend more each year as they adopt additional modules across the platform. With provider solutions growing organically at roughly double the pace of patient-payment solutions, cross-selling more of the suite into an already-large installed base is a durable growth engine. High switching costs in mission-critical billing systems reinforce the stickiness.
3. Iodine acquisition and platform breadth
The Iodine Software acquisition extended Waystar into mid-cycle and clinical-integrity capabilities, and management has said the integration is running ahead of schedule. Bolting complementary capabilities onto one platform lets Waystar sell a broader footprint to the same providers. Continued M&A and cross-sell of acquired capabilities are central to the growth story.
4. Structural demand for billing efficiency
US healthcare billing is famously complex, and providers face persistent margin pressure that makes faster, cleaner collections valuable. The addressable market for RCM software and transactions is often estimated in the $15-20 billion range annually. As a scaled independent platform, Waystar is positioned to consolidate share as providers move off fragmented legacy tools.
What are the risks to WAY?
Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a mid-30s P/E leaves little room for a growth or margin stumble, and the stock has traded well below its 52-week high. Growth is partly acquisition-fueled, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history. Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.
How is WAY valued? (as of JULY 2026)
Snapshot for WAY as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$1.16B
- Market cap: ~$4.6B
- Net income (TTM): ~$126M
- P/E ratio: ~35x
- Adj. EBITDA margin (Q1 2026): ~43%
- 2026 revenue guidance: ~$1.274B to $1.294B
Waystar was trading around $24 in early July 2026, well below its 52-week high, with about 192 million shares outstanding. Q1 2026 revenue rose ~22% year over year to ~$314 million (roughly 11% organic) with net revenue retention near 111%. The mid-30s P/E and a market cap several times trailing revenue reflect expectations for continued double-digit growth and margin expansion rather than a cheap-value setup.
How do you decide if WAY is a buy?
Rather than asking whether WAY is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold WAY indirectly through an index or sector ETF before adding more.
For the full picture, see the WAY stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about WAY against your real portfolio and see your actual exposure before deciding.
The bottom line on WAY
The bottom line: Waystar Holding's story right now is AI-driven revenue cycle automation, with revenue (ttm) at ~$1.16B. If you believe that narrative continues, the call is about sizing WAY sensibly and checking overlap with what you own; if you doubt it (the risk: concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around WAY with Walnut
Use Waystar Holding as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is WAY a good stock to buy right now?
+
The case for Waystar Holding right now is AI-driven revenue cycle automation, with revenue (ttm) at ~$1.16B. If you believe that thesis holds, WAY is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Waystar Holding do?
+
Waystar Holding (Nasdaq: WAY) sells cloud-based software that healthcare providers use to get paid: financial clearance and eligibility, claims and payer-payment management, denial
What are the main risks of WAY?
+
Concentration and competition are real: Optum (UnitedHealth) can bundle RCM with payer services and undercut on price, while R1 RCM, Availity, and Experian Health all compete for overlapping share. Valuation is the sharpest risk, as a mid-30s P/E leaves little room for a growth or margin stumble, and the stock has traded well below its 52-week high. Growth is partly acquisition-fueled, so integration missteps or slowing organic growth would matter, and the business carries meaningful debt from its buyout and IPO history. Regulatory change in healthcare reimbursement, payer-side pricing pressure, and cybersecurity exposure (a systemic concern for healthcare-payments infrastructure after the 2024 Change Healthcare breach) round out the risk set.
What does Waystar (WAY) do?
+
Waystar provides cloud-based software that healthcare providers use to get paid. Its platform handles eligibility and financial clearance, claims and payer-payment management, denials prevention and recovery, patient payments, and analytics, processing billions of transactions a year across roughly a million providers.
Is Waystar profitable?
+
Yes. After its 2024 IPO, Waystar turned GAAP-profitable, reporting roughly $126 million in trailing-twelve-month net income as of mid-2026 and adjusted EBITDA margins in the low-40s percent. Q1 2026 net income was about $43 million.
How fast is Waystar growing?
+
Revenue grew about 22% year over year in Q1 2026 to roughly $314 million, of which about 11% was organic and the rest came from the Iodine Software acquisition. Full-year 2026 revenue guidance is roughly $1.274 billion to $1.294 billion.
Who are Waystar's main competitors?
+
Chief competitors include Optum (UnitedHealth), which bundles RCM with payer services, and R1 RCM in full-service outsourcing. On clearinghouse and eligibility technology, Waystar competes most directly with Availity and Experian Health.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell WAY; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.